Recombinant PDCD1 (Cemiplimab Biosimilar) antibody

Catalog No. ABIN7795092

The Mouse Monoclonal anti-PDCD1 (Cemiplimab Biosimilar) antibody is suitable to detect PDCD1 (Cemiplimab Biosimilar) in samples from Human. It has been validated for FACS and in vivo.

Quick Overview for Recombinant PDCD1 (Cemiplimab Biosimilar) antibody (ABIN7795092)

Target: PDCD1 (Cemiplimab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Mouse

Clonality: Monoclonal

Conjugate: This PDCD1 (Cemiplimab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-PDCD1 (Cemiplimab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Cemiplimab Biosimilar, PD-1 Monoclonal Antibody

Characteristics: Cemiplimab Biosimilar uses the same protein sequences as the therapeutic antibody cemiplimab. PD-L1 and PD-L2 (B2-DC or CD273, programmed cell death ligand 2) are the two ligands for the receptor PD-1 (CD279, programmed cell death protein 1). Cemiplimab (anti-PD-1) is an intravenous human monoclonal antibody directed against programmed cell death-1 receptor (PD-1) and blocks its interaction with programmed death ligands 1 (PD-L1) and 2 (PD-L2). Cemiplimab blocks T-cell inactivation and enhances the immune system's anti-tumor response. Binding of the programmed death receptor (PD) ligands PD-L1 and PD-L2, to the PD-1 receptor inhibits T-cell proliferation and cytokine production. The upregulation of PD-1 ligands occurs in some tumors and signaling through this pathway may contribute to the inhibition of active T-cell immune surveillance of tumors. Cemiplimab is a recombinant human immunoglobulin G4 (IgG4) monoclonal antibody that binds to the PD-1 receptor and blocks its interaction with PD-L1 and PD-L2 ligands, causing PD-1 pathway-mediated inhibition of the immune response, including the anti-tumor immune response. In mouse tumor models, blocking PD-1 activity resulted in decreased rates of tumor growth.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human PD1

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for PDCD1 (Cemiplimab Biosimilar)

Target: PDCD1 (Cemiplimab Biosimilar)

Alternative Name: Cemiplimab Biosimilar

Target Type: Biosimilar